Metraipolis › archive › dc_ea37bbbc34d5

Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative… — Europe PMC PMID:41415283

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41415283
DOI: 10.3389/fimmu.2025.1684759
License (as archived): solo-consultazione
Archived: 2026-11-07T23:24:24.621Z
SHA-256 of the archived text: 624de9683a2a8db07ab0f2d4bda6fc0e9ec03657c317805c8ff466d77a1aa1b0
Stable URL of this page: https://metraipolis.com/documento/dc_ea37bbbc34d5

How to cite

Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative… — Europe PMC PMID:41415283 — Europe PMC (en), https://europepmc.org/article/MED/41415283 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ea37bbbc34d5 (Metraipolis archive dc_ea37bbbc34d5, sha256 624de9683a2a8db07ab0f2d4bda6fc0e9ec03657c317805c8ff466d77a1aa1b0)

BibTeX

@misc{dcea37bbbc34d5,
  title = {Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative… — Europe PMC PMID:41415283},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41415283},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ea37bbbc34d5; sha256 624de9683a2a8db07ab0f2d4bda6fc0e9ec03657c317805c8ff466d77a1aa1b0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41415283. Agents can read the archived copy with the MCP tool read_document.